Stock IRLAB A IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

All News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:43 2024-05-31 am EDT 		5-day change 1st Jan Change
15.6 SEK -0.95% Intraday chart for IRLAB Therapeutics AB -0.95% +108.00%
May. 27 Sweden’s IRLAB Therapeutics Names New CEO MT
May. 27 IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IRLAB appoints Kristina Torfgard as new CEO
AQ
IRLAB presents at Redeye Growth Day 30 May
AQ
Sweden’s IRLAB Therapeutics Names New CEO
MT
IRLAB appoints Kristina Torfgård as new CEO
AQ
IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024
CI
IRLAB Therapeutics AB Strengthens Liquidity by Drawing SEK 25 Million on A Previously Secured Loan Facility
CI
IRLAB strengthens its liquidity by drawing SEK 25 million on a previously secured loan facility
AQ
Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB
AQ
IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757
CI
IRLAB has administered the first dose in a Phase I clinical trial with the drug candidate IRL757
AQ
IRLAB broadcasts the annual general meeting live
AQ
IRLAB presents at ABGSC Investor Days
AQ
Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
IRLAB publishes interim report for the period January-March 2024
AQ
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy
CI
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
AQ
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
CI
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757
AQ
IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. News IRLAB Therapeutics AB